FDA clears Instil Bio's IND for AXN-2510 cancer therapy

Instil Bio (NASDAQ: TIL) announced U.S. FDA Investigational New Drug (IND) clearance for AXN-2510, a PD-L1xVEGF bispecific antibody targeting solid tumors, with a Phase 1 trial planned for initiation by the end of 2025. This development follows a significant 118% stock gain over the past year, as analysts like H.C. Wainwright have raised price targets to $125, citing promising Phase 1/2 data showing a 23% overall response rate in non-small cell lung cancer. The company also anticipates initial Phase 2 safety and efficacy results from its partner ImmuneOnco for AXN-2510 in China during the second half of 2025, highlighting increasing industry interest in PD-L1xVEGF bispecifics.

Analysis

Instil Bio (TIL) has achieved a significant clinical milestone with the U.S. FDA's clearance of its Investigational New Drug (IND) application for AXN-2510, a PD-L1xVEGF bispecific antibody. This clearance paves the way for a Phase 1 monotherapy trial for solid tumors, slated to begin by the end of 2025. The company's lead asset is supported by promising early data, including a 23% overall response rate observed in a prior Phase 1/2 dose escalation trial, which analysts at H.C. Wainwright deemed competitive. This positive clinical signal underpins their reaffirmed "Buy" rating and an increased price target of $125, suggesting substantial upside from the current price of $21.93. Further validation is anticipated from a partner-led Phase 2 study in China, with initial results expected in the second half of 2025. Despite a remarkable 118% stock return over the past year, InvestingPro data suggests the stock is trading near its fair value, and JMP analysts maintain a more neutral "Market Perform" rating. The company's strategic focus is validated by broader industry interest in this drug class, evidenced by the BioNTech and Bristol-Myers Squibb partnership. Financially, Instil Bio exhibits a strong liquidity position with current assets exceeding short-term obligations, which is a positive for a clinical-stage company.

Key Decisions for Investors

• Given the FDA IND clearance and promising early clinical data, investors with a high-risk tolerance may consider the stock for its long-term potential, particularly noting the significant gap between the current price and H.C. Wainwright's $125 target.
• Monitor key upcoming catalysts which will heavily influence the stock's trajectory: the initiation of the US Phase 1 trial by year-end 2025 and, more critically, the release of Phase 2 data from China in the second half of 2025.
• Despite the bullish catalysts, the stock's 118% appreciation in the past year and the split analyst ratings warrant caution; investors should weigh the potential for volatility and acknowledge that much of the near-term optimism may already be priced in, pending further definitive clinical results.